ReviewChemical science2025
A powerful bioorthogonal toolbox boosting the development of immune theranostics.
Review in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ChemBioParis 2025: Approaching Biology Through Chemistry in the City of Light.Chembiochem : a European journal of chemical biology · 2026Article
- Engineering Protease-Resistant Peptides via Non-Canonical Amino Acids: Design Strategies and Biosynthetic Advances.Bioengineering (Basel, Switzerland) · 2026Review
- Thiol-Retaining N-Terminal Cysteine Chemistry for Dual Modification and Bicyclic Peptide Construction.Journal of the American Chemical Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioorthogonal chemistry encompasses a series of rapid and selective reactions that proceed under physiological conditions without interfering with essential biological functions. Over the past few decades, benefiting from its simplicity and efficiency, bioorthogonal chemistry has provided non-chemists with a powerful toolbox to advance chemical biology research and develop innovative biomedical strategies, leading to significant breakthroughs in disease treatment. With a growing understanding of pathological biology and immunology, immune theranostics has emerged as a next-generation strategy for precise disease diagnosis and treatment, as exemplified by the clinical success of CAR-T cell therapy. Indeed, prevalent advances have demonstrated that bioorthogonal chemistry significantly facilitates the construction of immune theranostic platforms. Recognizing its growing importance, this review provides an overview of the ideal bioorthogonal reactions suitable for biomedical applications. Additionally, we systematically summarize promising bioorthogonal-enabled applications for the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.